Home/Pipeline/MP0317

MP0317

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Molecular Partners

About Molecular Partners

Molecular Partners AG is a pioneer in the development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, an entirely new class of custom-built protein drugs designed to overcome limitations of conventional biologics. The company leverages its proprietary platform to create multi-specific, logic-gated, and radio-conjugated drug candidates, primarily targeting cancers with high unmet need. Its strategy combines in-house R&D expertise with strategic partnerships to advance a diverse pipeline, including its lead programs MP0533 for AML and MP0712 for solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active